Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in KBG syndrome (N-of-1 series)
2023-506202-40-01Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of methylphenidate in KBG syndrome (KBG) and attention deficit hyperactivity disorder (ADHD), sponsored by Radboud University Medical Center. Primary endpoint: Strengths and Difficulties Questionnaire (SDQ), ADHD subscale. Planned start Jun 2024; status: authorised.
02
Drugs
methylphenidate
03
Conditions
KBG syndrome (KBG)attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2023-506202-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506202-40-01.